Advertisement
Singapore markets open in 53 minutes
  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • Dow

    39,375.87
    +67.87 (+0.17%)
     
  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     
  • Bitcoin USD

    55,740.31
    -2,449.92 (-4.21%)
     
  • CMC Crypto 200

    1,157.64
    -51.05 (-4.22%)
     
  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     
  • Gold

    2,394.10
    -3.60 (-0.15%)
     
  • Crude Oil

    83.17
    +0.01 (+0.01%)
     
  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     
  • Nikkei

    40,912.37
    0.00 (0.00%)
     
  • Hang Seng

    17,799.61
    -228.69 (-1.27%)
     
  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     
  • Jakarta Composite Index

    7,253.37
    -7,220.89 (-49.89%)
     
  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages.

Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend.

Over the past four weeks, IMGN has gained 89.4%. The company is currently ranked a Zacks Rank #2 (Buy), another strong indication the stock could move even higher.

ADVERTISEMENT

Looking at IMGN's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 9 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on IMGN for more gains in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research